<DOC>
	<DOCNO>NCT00580281</DOCNO>
	<brief_summary>The drug take cancer , imatinib ( GleevecTM ) , recently show new type side effect . In people , imatinib affect bone make . The purpose study find imatinib cause side effect . We check bone form test blood urine . We also check bone strength special X-ray bone call bone density ( DEXA scan ) .</brief_summary>
	<brief_title>Effect Imatinib Bone Metabolism Patients With Chronic Myelogenous Leukemia Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description>Preliminary data institution suggest imatinib , likely inhibit platelet derive growth factor receptor ( PDGFR ) , inhibit bone formation resorption high percentage patient either chronic myelogenous leukemia ( CML ) gastrointestinal stromal tumor ( GIST ) .1 Some , , patient take imatinib develop hypophosphatemia effect bone , measure marker bone synthesis metabolism , see patient normal phosphate level well . Marked urinary phosphate wasting elevate level parathyroid hormone see nearly patient . The effect imatinib bone may dose-related . Patients hypophosphatemia routinely start oral phosphate replacement , follow determination urinary phosphate wasting perform . The clinical consequence abnormalities bone yet know . This trial study 60 patient CML chronic phase , early accelerate phase ( detected cytogenetics ) GIST already take imatinib . Parameters relate bone metabolism check every 3 month 2 year . We determine incidence bone abnormality treat population , determine whether fast serum phosphate predict change bone metabolism , determine whether change bone density measure serial bone densitometry , determine whether oral phosphate replacement restore phosphate balance , determine whether dose effect imatinib parameter bone metabolism .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients CML chronic phase , accelerate phase base cytogenetic abnormality addition Philadelphia chromosome le 5 % blast , GIST take imatinib Patients life expectancy least 12 month ; patient must imatinib time study entry . Ability sign inform consent and/or assent Patients know parathyroid disorder ; active thyroid disorder except stable , replaced hypothyroidism ; Cushing 's syndrome ; uncontrolled diabetes mellitus ( could unexpected fluid , electrolyte mineral shift ) ; sarcoidosis ( elevate calcitriol level granulomata ) ; hypercalcemia malignancy ( i.e. , PTHrPmediated extensive bone mets ) ; know tumorinduced osteomalacia ; Paget 's disease bone ; know Xlinged autosomal dominant hypophosphatemic rickets/osteomalacia ; know renal tubular disease ( e.g. , Fanconi 's syndrome ) ; chronic GI malabsorption sydrome . Patients take oral calcium excess calcium 750 mg Vitamin D 400 mg daily ( ie , contain single multivitamin ) . Patients take amount may eligible study vitamin mineral supplementation excess stop minimum 2 week prior study entry . Patients take oral intravenous steroid , calcitonin , selective estrogen modulate agent tamoxifen raloxifene , gallium nitrate , bone seek radionuceotides , calcimimetic agent cinacalet . Patients prior treatment cisplatin , carboplatin , oxaliplatin , ifosfamide , cyclophosphamide .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Gleevec</keyword>
</DOC>